Extract of Audited Standalone Financial Results Copy of Newspaper Advertisement
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jagsonpal Pharmaceuticals has submitted copies of its newspaper advertisement published on May 08, 2025 in Business Standard (English and Hindi), containing the audited standalone financial results for Q4 and full year ended March 31, 2025. Total income from operations for FY25 stood at Rs. 613.30 million in Q4 (vs Rs. 459.73 million in Q4 FY24) and Rs. 2,769.06 million for the full year (vs Rs. 2,179.81 million in FY24), a growth of about 27% year-on-year. Profit after tax for FY25 jumped to Rs. 553.61 million, more than doubling from Rs. 224.63 million in FY24. Q4 FY25 profit after tax came in at Rs. 65.83 million (vs Rs. 35.49 million in Q4 FY24). Basic EPS for the full year rose to Rs. 8.26 from Rs. 3.40. The board has also recommended a final dividend of Rs. 2.50 per share (125% on face value of Rs. 2), subject to shareholder approval.
Strong double-digit revenue growth and a sharp jump in full-year profit signal healthy business momentum, which should be viewed positively by shareholders. The 125% final dividend declaration also reflects robust cash generation and rewards long-term holders.